| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity Indicators
NEW YORK, July 24, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ:KLTO) (the "Company" or "Klotho") announced today that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity.
In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life.
Posted In: KLTO
